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Abstract
‘Mapping’ onto generic preference-based outcome measures is increasingly being used as a means of
generating health utilities for use within health economic evaluations. Despite publication of technical guides
for the conduct of mapping research, guidance for the reporting of mapping studies is currently lacking. The
MAPS (MApping onto Preference-based measures reporting Standards) statement is a new checklist, which
aims to promote complete and transparent reporting of mapping studies. The primary audiences for the
MAPS statement are researchers reporting mapping studies, the funders of the research, and peer
reviewers and editors involved in assessing mapping studies for publication.
A de novo list of 29 candidate reporting items and accompanying explanations was created by a working
group comprised of six health economists and one Delphi methodologist. Following a two-round, modified
Delphi survey with representatives from academia, consultancy, health technology assessment agencies
and the biomedical journal editorial community, a final set of 23 items deemed essential for transparent
reporting, and accompanying explanations, was developed. The items are contained in a user friendly 23
item checklist. They are presented numerically and categorised within six sections, namely: (i) title and
abstract; (ii) introduction; (iii) methods; (iv) results; (v) discussion; and (vi) other. The MAPS statement is best
applied in conjunction with the accompanying MAPS explanation and elaboration document.
It is anticipated that the MAPS statement will improve the clarity, transparency and completeness of
reporting of mapping studies. To facilitate dissemination and uptake, the MAPS statement is being co-
published by seven health economics and quality of life journals, and broader endorsement is encouraged.
The MAPS working group plans to assess the need for an update of the reporting checklist in five years’ time.
Introduction
The process of ‘mapping’ onto generic preference-based outcome measures is
increasingly being used as a means of generating health utilities for application
within health economic evaluations1. Mapping involves the development and
use of an algorithm (or algorithms) to predict the primary outputs of generic
preference-based outcome measures, i.e. health utility values, using data on
other indicators or measures of health. The source predictive measure may be
a non-preference based indicator or measure of health outcome or, more excep-
tionally, a preference-based outcome measure that is not preferred by the local
health technology assessment agency. The algorithm(s) can subsequently be
applied to data from clinical trials, observational studies or economic models
containing the source predictive measure(s) to predict health utility values in
contexts where the target generic preference-based measure is absent. The pre-
dicted health utility values can then be analysed using standard methods for
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individual-level data (e.g. within a trial-based economic
evaluation), or summarised for each health state within a
decision-analytic model.
Over recent years there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values, and databases of published stu-
dies in this field are beginning to emerge2. Some authors3
and agencies4 concerned with technology appraisals have
issued technical guides for the conduct of mapping
research. However, guidance for the reporting of mapping
studies is currently lacking. In keeping with health-related
research more broadly5, mapping studies should be
reported fully and transparently to allow readers to assess
the relative merits of the investigation6. Moreover, there
may be significant opportunity costs associated with regu-
latory and reimbursement decisions for new technologies
informed by misleading findings from mapping studies.
This has led to the development of the MAPS
(MApping onto Preference-based measures reporting
Standards) reporting statement, which we summarise in
this paper.
The aim of the MAPS reporting statement is to provide
recommendations, in the form of a checklist of essential
items, which authors should consider when reporting a
mapping study. It is anticipated that the checklist will pro-
mote complete and transparent reporting by researchers.
The focus, therefore, is on promoting the quality of report-
ing of mapping studies, rather than the quality of their
conduct, although it is possible that the reporting state-
ment will also indirectly enhance the methodological
rigour of the research7. The MAPS reporting statement
is primarily targeted at researchers developing mapping
algorithms, the funders of the research, and peer reviewers
and editors involved in the manuscript review process for
mapping studies5,6. In developing the reporting statement,
the term ‘mapping’ is used to cover all approaches that
predict the outputs of generic preference-based outcome
measures using data on other indicators or measures of
health, and encompasses related forms of nomenclature
used by some researchers, such as ‘cross-walking’ or ‘trans-
fer to utility’1,8. Similarly, the term ‘algorithm’ is used in its
broadest sense to encompass statistical associations and
more complex series of operations.
The development of the MAPS statement
The development of the MAPS reporting statement was
informed by recently published guidance for health
research reporting guidelines5 and broadly modelled
other recent reporting guideline developments9–14.
A working group comprised of six health economists
(SP, ORA, HD, LL, MO, AG) and one Delphi method-
ologist (RF) was formed following a request from an
academic journal to develop a reporting statement for
mapping studies. One of the working group members
(HD) had previously conducted a systematic review of
studies mapping from clinical or health-related quality of
life measures onto the EQ-5D2. Using the search terms
from this systematic review, as well as other relevant art-
icles and reports already in our possession, a broad search
for reporting guidelines for mapping studies was con-
ducted. This confirmed that no previous reporting
guidance had been published. The working group members
therefore developed a preliminary de novo list of 29 report-
ing items and accompanying explanations. Following
further review by the working group members, this was
subsequently distilled into a list of 25 reporting items
and accompanying explanations.
Members of the working group identified 62 possible
candidates for a Delphi panel from a pool of active
researchers and stakeholders in this field. The candidates
included individuals from academic and consultancy set-
tings with considerable experience in mapping research,
representatives from health technology assessment agen-
cies that routinely appraise evidence informed by mapping
studies, and biomedical journal editors. Health economists
from the MAPS working group were included in the
Delphi panel. A total of 48 of the 62 (77.4%) individuals
agreed to participate in a Delphi survey aimed at develop-
ing a minimum set of standard reporting requirements for
mapping studies with an accompanying reporting
checklist.
The Delphi panellists were sent a personalised link to a
Web-based survey, which had been piloted by members of
the working group. Non-responders were sent up to two
reminders after 14 and 21 days. The panellists were ano-
nymous to each other throughout the study and their
identities were known only to one member of the working
group. The panellists were invited to rate the importance
of each of the 25 candidate reporting items identified by
the working group on a 9-point rating scale (1, ‘‘not
important’’, to 9, ‘‘extremely important’’); describe their
confidence in their ratings (‘‘not confident’’, ‘‘somewhat
confident’’ or ‘‘very confident’’); comment on the candi-
date items and their explanations; suggest additional items
for consideration by the panellists in subsequent rounds;
and to provide any other general comments. The candi-
date reporting items were ordered within six sections:
(i) title and abstract; (ii) introduction; (iii) methods;
(iv) results; (v) discussion; and (vi) other. The panellists
also provided information about their geographical area of
work, gender, and primary and additional work environ-
ments. The data were imported into Stata (version 13;
Stata-Corp, College Station, TX) for analysis.
A modified version of the Research ANd Development
(RAND)/University of California Los Angeles (UCLA)
appropriateness method was used to analyse the round
one responses15. This involved calculating the median
score, the inter-percentile range (IPR) (30th and 70th),
Journal of Medical Economics 2015
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and the inter-percentile range adjusted for symmetry
(IPRAS), for each item (i) being rated. The IPRAS
includes a correction factor for asymmetric ratings, and
panel disagreement was judged to be present in cases
if IPRi4IPRASi
15. We modified the RAND/UCLA
approach by asking panellists about ‘importance’ rather
than ‘appropriateness’ per se. Assessment of importance
followed the classic RAND/UCLA definitions, cate-
gorised simply as whether the median rating fell between
1 and 3 (unimportant), 4 and 6 (neither unimportant nor
important), or 7 and 9 (important)15.
The results of round one of the Delphi survey were
reviewed at a face-to-face meeting of the working group.
A total of 46 of the 48 (95.8%) individuals who agreed to
participate completed round one of the survey. Of the 25
items, 24 were rated as important, with one item (‘‘Source
of Funding’’) rated as neither unimportant nor important.
There was no evidence of disagreement on ratings of any
items according to the RAND/UCLAmethod. These find-
ings did not change when the responses of the MAPS
working group were excluded. Based on the qualitative
feedback received in round one, items describing
‘‘Modelling Approaches’’ and ‘‘Repeated Measurements’’
were merged, as were items describing ‘‘Model
Diagnostics’’ and ‘‘Model Plausibility’’. In addition,
amendments to the wording of several recommendations
and their explanations were made in the light of qualita-
tive feedback from the panellists.
Panellists participating in round one were invited to
participate in a second round of the Delphi survey. A sum-
mary of revisions made following round one was provided.
This included a document in which revisions to each of the
recommendations and explanations were displayed in the
form of track changes. Panellists participating in round two
were provided with group outputs (mean scores and
their standard deviations, median scores and their IPRs,
histograms and RAND/UCLA labels of importance and
agreement level) summarising the round one results (and
disaggregated outputs for the merged items). They were
also able to view their own round one scores for each
item (and disaggregated scores for the merged items).
Panellists participating in round two were offered the
opportunity to revise their rating of the importance of
each of the items and informed that their rating from
round one would otherwise hold. For the merged items,
new ratings were solicited. Panellists participating in
round two were also offered the opportunity to provide
any further comments on each item or any further infor-
mation that might be helpful to the group. Non-responders
to the second round of the Delphi survey were sent up to
two reminders after 14 and 21 days. The analytical
methods for the round two data mirrored those for the
first round.
The results of the second round of the Delphi
survey were reviewed at a face-to-face meeting of the
working group. A total of 39 of the 46 (84.8%) panellists
participating in round one completed round two of the
survey. All 23 items included in the second round were
rated as important with no evidence of disagreement on
ratings of any items according to the RAND/UCLA
method. Qualitative feedback from the panellists partici-
pating in round two led to minor modifications to wording
of a small number of recommendations and their explan-
ations. This was fed back to the round two respondents
who were given a final opportunity to comment on the
readability of the final set of recommendations and explan-
ations. Based on these methods, a final consensus list of 23
reporting items was developed.
The MAPS statement
The MAPS statement is a 23-item checklist of recommen-
dations (Table 1) that we consider essential for complete
and transparent reporting of studies that map onto generic
preference-based outcome measures. The 23 reporting
items are presented numerically and categorised within
six sections, namely: (i) title and abstract (2 items); (ii)
introduction (2 items); (iii) methods (9 items); (iv) results
(6 items); (v) discussion (3 items); and (vi) other (1 item).
The reporting of each item does not necessarily have to
follow the order within the MAPS statement. Rather,
what is important is that each recommendation is
addressed either in the main body of the report or its
appendices. Several biomedical journals have endorsed
the MAPS statement. These include Applied Health
Economics and Health Policy, Health and Quality of Life
Outcomes, International Journal of Technology Assessment
in Health Care, Journal of Medical Economics, Medical
Decision Making, PharmacoEconomics and Quality of Life
Research. We encourage other journals and research inter-
est groups to endorse the MAPS statement and authors to
adhere to its principles.
The MAPS Explanation and Elaboration
paper
In addition to the MAPS reporting statement, we have
produced a supporting Explanation and Elaboration
paper16 modelled on those developed for other reporting
guidelines9–14. The reporting items contained within the
MAPS statement are best understood by referring to the
information contained within this accompanying docu-
ment. The Explanation and Elaboration paper provides
exemplars of good reporting practice identified from the
published literature for each reporting item. In addition, it
provides a detailed explanation to accompany each recom-
mendation, supported by a rationale and relevant evidence
where available. The development of the Explanation and
Journal of Medical Economics 2015
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Table 1. Checklist of items to include when reporting a mapping study.
Section/Topic Item Number Recommendation Reported on Page Number/
Line Number
Title and abstract
Title 1 Identify the report as a study mapping between
outcome measures. State the source meas-
ure(s) and generic, preference-based target
measure(s) used in the study.
_____________
Abstract 2 Provide a structured abstract including, as
applicable: objectives; methods, including data
sources and their key characteristics, outcome
measures used and estimation and validation
strategies; results, including indicators of
model performance; conclusions; and impli-
cations of key findings.
_____________
Introduction
Study rationale 3 Describe the rationale for the mapping study in the
context of the broader evidence base.
_____________
Study objective 4 Specify the research question with reference to
the source and target measures used and the
disease or population context of the study.
_____________
Methods
Estimation sample 5 Describe how the estimation sample was identi-
fied, why it was selected, the methods of
recruitment and data collection, and its loca-
tion(s) or setting(s).
_____________
External validation sample 6 If an external validation sample was used, the
rationale for selection, the methods of
recruitment and data collection, and its loca-
tion(s) or setting(s) should be described.
____________
Source and Target measures 7 Describe the source and target measures and the
methods by which they were applied in the
mapping study.
_____________
Exploratory data analysis 8 Describe the methods used to assess the degree
of conceptual overlap between the source and
target measures.
_____________
Missing data 9 State how much data were missing and how
missing data were handled in the sample(s)
used for the analyses.
_____________
Modelling approaches 10 Describe and justify the statistical model(s) used
to develop the mapping algorithm.
_____________
Estimation of predicted scores
or utilities
11 Describe how predicted scores or utilities are
estimated for each model specification.
_____________
Validation methods 12 Describe and justify the methods used to validate
the mapping algorithm.
_____________
Measures of model performance 13 State and justify the measure(s) of model per-
formance that determine the choice of the
preferred model(s) and describe how these
measures were estimated and applied.
_____________
Results
Final sample size(s) 14 State the size of the estimation sample and
any validation sample(s) used in the analyses
(including both number of individuals and
number of observations).
_____________
Descriptive information 15 Describe the characteristics of individuals in the
sample(s) (or refer back to previous publica-
tions giving such information). Provide sum-
mary scores for source and target measures,
and summarise results of analyses used to
assess overlap between the source and target
measures.
_____________
Model selection 16 State which model(s) is(are) preferred and justify
why this(these) model(s) was(were) chosen.
_____________
Model coefficients 17 Provide all model coefficients and standard errors
for the selected model(s). Provide clear guid-
ance on how a user can calculate utility scores
based on the outputs of the selected model(s).
_____________
(continued )
Journal of Medical Economics 2015
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Elaboration paper was completed following several iter-
ations produced by members of the working group, after
which the examples and explanations were shared with the
Delphi panellists for final revisions to improve readability
and their approval. The Explanation and Elaboration
paper also summarises the characteristics of the Delphi
panellists and provides detailed statistics for item ratings
at each Delphi round.
Discussion
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values. One recent review article iden-
tified ninety studies published up to the year 2013
reporting 121 mapping algorithms between clinical or
health-related quality of life measures and the EQ-5D2.
That review article excluded mapping algorithms targeted
at other generic preference-based outcome measures that
can generate health utilities, such as the SF-6D17 and the
Health Utilities Index (HUI)18, which have been the tar-
get of numerous other mapping algorithms (e.g.19–24,1).
Moreover, the popularity of the mapping approach for
estimating health utilities is unlikely to wane given the
numerous contexts within health economic evaluation
where primary data collection is challenging. However,
mapping introduces additional uncertainty and collection
of primary data with the preferred utility instrument is
preferable.
The MAPS reporting statement was developed to pro-
vide recommendations, in the form of a checklist of essen-
tial items, which authors should consider when reporting
mapping studies. Guidance for the reporting of mapping
studies was not previously available in the literature. The
overall aim of MAPS is to promote clarity, transparency
and completeness of reporting of mapping studies. It is not
intended to act as a methodological guide, nor as a tool for
assessing the quality of study methodology. Rather, it aims
to avoid misleading conclusions being drawn by readers,
and ultimately policy makers, as a result of sub-optimal
reporting. In keeping with other recent health research
reporting guidelines, we have also produced an accom-
panying Explanation and Elaboration paper16 to facilitate
a deeper understanding of the 23 items contained within
the MAPS reporting statement. That paper should hope-
fully act as a pedagogical framework for researchers report-
ing mapping studies.
The development of the MAPS reporting statement,
and its Explanation and Elaboration document, was
framed by recently published guidance for health research
reporting guidelines5. The Delphi panel was composed of a
multi-disciplinary, multi-national team of content experts
and journal editors. The panel members included people
experienced in conducting mapping studies; of the 84
researchers who were first authors on papers included in
a recent review of EQ-5D mapping studies2, 31 (36.9%)
Table 1. Continued.
Section/Topic Item Number Recommendation Reported on Page Number/
Line Number
Uncertainty 18 Report information that enables users to estimate
standard errors around mean utility predictions
and individual-level variability.
_____________
Model performance and face validity 19 Present results of model performance, such as
measures of prediction accuracy and fit stat-
istics for the selected model(s) in a table or in
the text. Provide an assessment of face validity
of the selected model(s).
_____________
Discussion
Comparisons with previous studies 20 Report details of previously published studies
developing mapping algorithms between the
same source and target measures and
describe differences between the algorithms,
in terms of model performance, predictions
and coefficients, if applicable.
_____________
Study limitations 21 Outline the potential limitations of the mapping
algorithm.
_____________
Scope of applications 22 Outline the clinical and research settings in which
the mapping algorithm could be used.
_____________
Other
Additional information 23 Describe the source(s) of funding and non-mon-
etary support for the study, and the role of
the funder(s) in its design, conduct and report.
Report any conflicts of interest surrounding the
roles of authors and funders.
_____________
Journal of Medical Economics 2015
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were included as panellists. We have no evidence to
believe that a larger panel would have altered the final
set of recommendations. The Delphi methodologies that
we applied included analytical approaches only recently
adopted by developers of health reporting guidelines15.
We are unable to assess whether a strict adherence to
the MAPS checklist will increase the word counts of map-
ping reports. It is our view that the increasing use of online
appendices by journals should permit comprehensive
reporting even in the context of strict word limits for the
main body of reports.
Evidence for other health research reporting guidelines
suggests that reporting quality improved after the intro-
duction of reporting checklists25–27, although there is
currently no empirical evidence that adoption of MAPS
will improve the quality of reporting of mapping research.
Future research planned by the MAPS working group will
include a before and after evaluation of the benefits (and
indeed possible adverse effects) of the introduction of the
MAPS reporting statement. It will also be necessary to
update the MAPS reporting statement in the future to
address conceptual, methodological and practical
advances in the field. Potential methodological advances
that might be reflected in an update might include shifts
towards more complex model specifications, better
methods for dealing with uncertainty, and guidance on
appropriate use of measures of prediction accuracy, such
as mean absolute error (MAE) and mean square error
(MSE). The MAPS working group plans to assess the
need for an update of the reporting checklist in five
years’ time.
In conclusion, this paper summarises a new reporting
statement developed for studies that map onto generic
preference-based outcome measures. We encourage
health economic and quality of life journals to endorse
MAPS, promote its use in peer review and update their
editorial requirements and ‘Instructions to Authors’
accordingly.
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